Rapport de veille

Isomorphic Labs signs AI cancer drug design deal with MSD days after $5bn raise

The Alphabet AI drug discovery firm will design small molecule candidates for a cancer target using MSD data, with MSD handling development and commercialisation.

INSIGHTEX Editorial Desk

2 min de lecture

Isomorphic Labs signs AI cancer drug design deal with MSD days after $5bn raiseRapport de veille

What happened

Alphabet's Isomorphic Labs has agreed a research partnership with MSD to search for small molecule drug candidates against a cancer target that the companies consider strategically important, Silicon Republic reported. The project brings together the AI technology of Isomorphic Labs and the data resources held by MSD.

Isomorphic Labs will use in silico prediction, meaning computer-simulated experiments, to generate molecule designs, running MSD's data sets through its own drug design engine, IsoDDE. MSD will lead pre-clinical and clinical development, manufacturing and the commercial launch of any resulting medicines. Isomorphic Labs gets an upfront payment and may earn more as specified milestones are reached.

Sarah Skerratt, chief research officer at Isomorphic Labs, said the company would apply its drug design engine to a challenging programme to make significant discovery progress. George Addona, a senior vice-president at MSD Research Laboratories whose remit spans discovery, translational medicine and preclinical development, said effective use of AI and machine learning in molecule design depends on laboratory experiments and computational work being tightly coordinated, and that the pairing aims to produce better candidates faster.

Context

The agreement came in the same week that Isomorphic Labs said it had raised $5bn in Series C funding. Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and other new backers also invested, and Alphabet contributed a substantial amount. Earlier supporters Temasek, GV, Thrive Capital, CapitalG, the UK Sovereign AI Fund and MGX also took part.

Andreessen Horowitz profile

Sequoia Capital profile

SourceSilicon Republic

Le briefing

La semaine tech, en un seul e-mail.

Les dépêches qui méritent votre temps, chaque semaine. Désinscription à tout moment.